Project Grant K22CA285837
Award Date
1/1/25
Completion Date
12/31/27
Dollars Obligated
$195K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
This federal Project Grant award, funded by the National Cancer Institute's Cancer Biology Research program (CFDA 93.396), supports fundamental research into the role of long noncoding RNAs in acute myeloid leukemia (AML). The $415,259 award, which runs from August 1, 2024 to July 31, 2026, will be performed by the Rector & Visitors of the University of Virginia.
The key objectives of the project are to: 1) Determine the role of a specific regulatory RNA in primary and relapsed AML, and...
The National Cancer Institute (NCI) awarded a $458,698 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the Regents of the University of Michigan. The grant, titled "Genes Regulating Stem and Progenitor Cell Expansion and Relapse in Acute Myeloid Leukemia", aims to study novel genes that influence normal and leukemic stem/progenitor cell expansion, and their contributions to therapy resistance and relapse in acute myeloid leukemia (AML). The 5-year project...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $443,220 in funding to the Beckman Research Institute of the City of Hope to study the role, mechanism, and therapeutic potential of the RNA methyltransferase METTL1 in acute myeloid leukemia (AML). The research aims to: 1) further consolidate the importance of METTL1 function in AML using mouse models, 2) understand the role of the METTL1/tRNAPheGAA/HCK signaling axis...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $336,000 to the Van Andel Research Institute (VAI) to characterize the role of germline genetic variation and viral exposures as determinants of susceptibility to hematological diseases, particularly pediatric acute myeloid leukemia (AML). The research aims to identify genetic and viral factors that may interact with structural chromosomal variants to increase the risk of AML and...
The National Cancer Institute awarded The Johns Hopkins University a $145,642 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to support research on the role of the chromatin regulator HMGA1 in KMT2A-rearranged acute myeloid leukemia (KMT2A-R AML). The research aims to elucidate mechanisms by which HMGA1 drives leukemogenesis and therapy resistance in this aggressive form of leukemia, which is caused by rearrangements of the KMT2A gene. Specifically, the project will...
This $439,644 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports fundamental scientific investigations into the molecular and cellular mechanisms underlying acute myeloid leukemia (AML). The primary objectives are to: 1) investigate the relationship between specific mutations and leukemia stem cell frequency, disease initiation, and disease maintenance; 2) evaluate in vivo dynamics of individual AML stem cells using single-cell...
The federal Project Grant award of $160,642 from the National Cancer Institute's (NCI) Cancer Research Manpower program (CFDA 93.398) will support research to characterize the role of oncogenic NRAS mutations in acute myeloid leukemia (AML) with IDH1 mutations. The research aims to elucidate how NRAS mutations modulate the disease pathogenesis and therapeutic response to IDH1 inhibitors like ivosidenib. The project will leverage genetically engineered mouse models and patient-derived...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $192,240 to the Van Andel Research Institute (VAI) over 3 years (June 1, 2024 - May 31, 2027) to conduct research on oncoprotein-regulated lineage plasticity in acute leukemia. The key objectives are to: 1) Identify how KMT2A oncoproteins contribute to B-ALL to AML lineage switching events, and 2) Discover novel biomarkers and therapeutic approaches to target high-risk...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding for a research project focused on understanding the role of gain-of-function mutant p53 proteins in promoting leukemia-initiating cell (LIC) self-renewal, chromatin accessibility, and 3D chromatin structure in acute myeloid leukemia (AML).
The $662,938 award to Northwestern University aims to elucidate the mechanisms by which specific p53 mutations enhance LIC...
The National Cancer Institute (NCI) awarded a $101,948 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Van Andel Research Institute (VAI) to study the role of germline genetic variation and viral infection in the development and progression of pediatric acute myeloid leukemia (AML). The project aims to characterize germline variants and perform functional validation in a zebrafish model of high-risk pediatric AML during the F99 training phase. The K00...